Suprainguinal Fascia Iliaca Block vs. Adductor Canal Block for Analgesia After Total Knee Arthroplasty

NCT07739108 | Not Yet Recruiting

• 1 other identifier: TBEK 2026/05-20
• Study Type: interventional
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study evaluates the analgesic efficacy and motor-sparing properties of ultrasound-guided Suprainguinal Fascia Iliaca Block (S-FIB) compared with Adductor Canal Block (ACB) in patients undergoing primary total knee arthroplasty (TKA). The main hypothesis is that ACB better preserves quadriceps muscle strength, allowing earlier functional mobilization, while providing comparable (non-inferior) analgesia to S-FIB.

Conditions

Arthroplasty, Replacement, Knee

Keywords

Suprainguinal Fascia Iliaca Block Adductor Canal Block Ultrasound-Guided Nerve Block Quadriceps Muscle Strength Regional Anesthesia

Outcome Measures

Primary Outcomes (1)

• Postoperative Pain Intensity (NRS)

  Numerical Rating Scale (0-10) at rest and during active knee flexion (30°). Time Frame: Postoperative hours 2, 6, 12, 24, and 48.

  Postoperative hours 24 hour

Secondary Outcomes (4)

• Quadriceps Muscle Strength

  Postoperative hours 6 and 12.

• Cumulative Opioid Consumption

  24 and 48 hours postoperatively.

• Time to First Mobilization

  Up to 48 hours postoperatively.

• Quality of Recovery (QoR-15)

  Baseline (preoperative) and 24 hours postoperatively.

Study Arms (2)

S-FIB

ACTIVE COMPARATOR

Active ultrasound-guided Suprainguinal Fascia Iliaca Block

Drug: PCA

ACB

ACTIVE COMPARATOR

Active ultrasound-guided Adductor Canal Block

Drug: PCA

Interventions

PCA DRUG

All patients receive standardized spinal anesthesia and postoperative intravenous PCA tramadol within a standardized multimodal regimen.

ACB; S-FIB

Eligibility Criteria

• Age: 45 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• ASA Physical Status I, II, or III
• Scheduled for elective unilateral primary total knee arthroplasty
• Able to understand and operate the PCA device
• Written informed consent provided

You may not qualify if:

• Pre-existing lower-extremity neurological deficit or motor weakness (e.g., severe diabetic neuropathy)
• Chronic opioid use (\>30 mg oral morphine equivalents/day for \>3 months)
• Infection at the block site or systemic sepsis
• Coagulopathy or bleeding diathesis
• Allergy to local anesthetics or study medications
• Revision TKA or bilateral knee procedures
• Cognitive impairment or inability to perform mobility/pain assessments

Sponsors & Collaborators

• Bursa Yuksek Ihtisas Training and Research Hospital: lead

MeSH Terms

Interventions

Passive Cutaneous Anaphylaxis

Intervention Hierarchy (Ancestors)

Skin Tests; Immunologic Tests; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Investigative Techniques; Immunologic Techniques; Antigen-Antibody Reactions; Immune System Phenomena

Study Officials

• Korgün Ökmen, PhD.MD

  University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital, Department of Anesthesiology and Reanimation

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Korgün Ökmen

CONTACT

+905057081021; korgunokmen@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator.PhD.MD

Study Record Dates

• First Submitted: July 28, 2026
• First Posted: July 31, 2026
• Study Start (Estimated): August 12, 2026
• Primary Completion (Estimated): August 12, 2027
• Study Completion (Estimated): September 12, 2027
• Last Updated: July 31, 2026

Record last verified: 2026-07